Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Durable responses with anti-BCMA CAR T-cell for multiple myeloma
Key clinical point: Cilta-cel was associated with rapid, deep, and durable responses in patients with heavily pretreated multiple myeloma.Major finding: The overall response rate was 96.9%, with most responses VGPR or better.
Study details: Prospective phase 1b/2 trial in 97 patients with relapsed/refractory multiple myeloma.
Disclosures: The study was sponsored by Janssen Research & Development and Legend Biotech. Dr. Madduri disclosed honoraria, consultancy, and speakers bureau activities for those companies and others.
Citation:
Madduri D et al. ASH 2020. Abstract 177.